The stock has a 36-month beta value of 1.21. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XENE is 73.30M, and at present, short sellers hold a 4.75% of that float. On January 20, 2025, the average trading volume of XENE was 401.17K shares.
XENE) stock’s latest price update
Xenon Pharmaceuticals Inc (NASDAQ: XENE)’s stock price has gone decline by -2.78 in comparison to its previous close of 39.62, however, the company has experienced a 0.29% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-01-16 that Xenon Pharmaceuticals’ Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time.
XENE’s Market Performance
XENE’s stock has risen by 0.29% in the past week, with a monthly drop of -6.75% and a quarterly drop of -9.62%. The volatility ratio for the week is 3.96% while the volatility levels for the last 30 days are 3.72% for Xenon Pharmaceuticals Inc. The simple moving average for the past 20 days is -1.95% for XENE’s stock, with a -4.86% simple moving average for the past 200 days.
Analysts’ Opinion of XENE
Many brokerage firms have already submitted their reports for XENE stocks, with Raymond James repeating the rating for XENE by listing it as a “Outperform.” The predicted price for XENE in the upcoming period, according to Raymond James is $50 based on the research report published on October 10, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see XENE reach a price target of $53. The rating they have provided for XENE stocks is “Buy” according to the report published on October 01st, 2024.
Citigroup gave a rating of “Buy” to XENE, setting the target price at $62 in the report published on January 04th of the previous year.
XENE Trading at -5.71% from the 50-Day Moving Average
After a stumble in the market that brought XENE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.46% of loss for the given period.
Volatility was left at 3.72%, however, over the last 30 days, the volatility rate increased by 3.96%, as shares sank -6.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.65% lower at present.
During the last 5 trading sessions, XENE rose by +0.29%, which changed the moving average for the period of 200-days by -7.11% in comparison to the 20-day moving average, which settled at $39.29. In addition, Xenon Pharmaceuticals Inc saw -1.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XENE starting from AULIN SHERRY, who sale 18,709 shares at the price of $41.21 back on Dec 18 ’24. After this action, AULIN SHERRY now owns 0 shares of Xenon Pharmaceuticals Inc, valued at $770,912 using the latest closing price.
SHERRY AULIN, the Officer of Xenon Pharmaceuticals Inc, proposed sale 18,709 shares at $41.21 during a trade that took place back on Dec 18 ’24, which means that SHERRY AULIN is holding shares at $770,909 based on the most recent closing price.
Stock Fundamentals for XENE
Current profitability levels for the company are sitting at:
- -47.49 for the present operating margin
- 0.61 for the gross margin
The net margin for Xenon Pharmaceuticals Inc stands at -39.66. The total capital return value is set at -0.32. Equity return is now at value -29.75, with -28.32 for asset returns.
Based on Xenon Pharmaceuticals Inc (XENE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -16.42. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -33.56.
Currently, EBITDA for the company is -210.51 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 531.4. The receivables turnover for the company is 5.74for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.21.
Conclusion
To sum up, Xenon Pharmaceuticals Inc (XENE) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
